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http://dx.doi.org/10.1016/j.ccell.2014.10.012SUMMARYIntratumoral heterogeneity plays a critical role in tumor evolution. To define the contribution of DNA methyl-
ation to heterogeneity within tumors, we performed genome-scale bisulfite sequencing of 104 primary
chronic lymphocytic leukemias (CLLs). Compared with 26 normal B cell samples, CLLs consistently dis-
played higher intrasample variability of DNAmethylation patterns across the genome, which appears to arise
from stochastically disordered methylation in malignant cells. Transcriptome analysis of bulk and single CLL
cells revealed that methylation disorder was linked to low-level expression. Disordered methylation was
further associated with adverse clinical outcome. We therefore propose that disordered methylation plays
a similar role to that of genetic instability, enhancing the ability of cancer cells to search for superior evolu-
tionary trajectories.INTRODUCTION
Cancer evolution is a central obstacle to achieving cure, as treat-
ment-resistant disease often emerges even in the context ofSignificance
Although it is well established that genetic intratumoral diversit
netic diversity in primary cancer samples and its impact on evo
we demonstrated a higher degree of intratumoral heterogeneit
heterogeneity stems from seemingly stochastic variation, rem
wherein stochastic variation is subjected to selection in tumor e
differences between normal and cancer cells and will facilitat
result from background stochastic variation versus positive se
Cahighly effective therapies. Recent studies by us and others
have demonstrated the contribution of genetic heterogeneity
within each individual cancer to clonal evolution and its impact
on clinical outcome (reviewed in Landau et al., 2014). In additiony fuels tumor evolution, relatively little is known about epige-
lution and outcomes. Using a variety of molecular platforms,
y of DNAmethylation in CLL. We have further shown that this
iniscent of the model of genetic heterogeneity in cancer,
volution. These data transform the way we viewmethylation
e the crucial distinction between epigenetic alterations that
lection, in this leukemia and other cancers.
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Figure 1. Higher DNA Methylation Intra-
sample Heterogeneity in CLL Arises from
Locally Disordered Methylation
(A) CLL global and CGI methylation compared
with normal B cells, measured with WGBS (top).
Cumulative distribution analysis (bottom) enables
the comparison of the proportion of intermediate
methylation values in WGBS data of CLL and B
cells from healthy adult volunteers (also see Fig-
ure S1).
(B) Mean intrasample CpG variance measured
with RRBS.
(C) Methylation patterns from RRBS data of a CLL
sample (CLL007) show two patterns of methyl-
ation (black circles, methylated CpGs; white cir-
cles, unmethylated): (1) a pattern compatible with
a mixture of cell populations with clear but distinct
methylation states for a particular nonimprinted
locus (left-SDHAP3 promoter [chr5:1594239-
1594268]) and (2) a pattern compatible with an
admixture of cells with locally disordered methyl-
ation (right-PIK3R5 promoter [chr17:8869616-
8869640]).
(D) A comparison between the intrasample CpG
variance that arises from discordant compared
with concordant reads across the 104 CLLs.
(E) CpG methylation and the PDR were calculated
as shown.
(F) Sample average PDR for CLL, cancer cell
lines, normal B cells, and a collection of primary
healthy human tissues. To enable an accurate
comparison between samples, sample average
PDR is calculated on the basis of a consensus
set of 63,443 CpGs that are covered with
greater than ten reads in >75% of all 202 RRBS
samples.
See also Figure S1 and Tables S1 and S2.
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Methylation Disorder and Intratumoral Heterogeneityto genetic mutations, somatic epigenetic alterations are also
drivers of neoplastic transformation and fitness (Baylin, 2005;
Baylin and Jones, 2011). Moreover, genetically uniform cells
exhibit phenotypic variation in essential properties such as sur-
vival capacity and proliferative potential (Kreso et al., 2013;
Spencer et al., 2009), likely reflecting epigenetic variation.
Hence, a priority in cancer biology is to measure intratumoral
heterogeneity at the epigenetic level and determine how somatic
genetic and epigenetic heterogeneity together affect tumor
evolution.
To examine these critical questions, we focused on chronic
lymphocytic leukemia (CLL), a malignancy of mature B cells
with well-documented epigenetic dysregulation of CLL-associ-
ated genes (Raval et al., 2007; Yuille et al., 2001). Stable dif-
ferences have been observed in DNA methylation across CLL
samples compared with normal B cells as well as between sub-
types of CLL (e.g., with mutated versus unmutated IGHV) (Cahill
et al., 2013; Harris et al., 2010; Kulis et al., 2012; Pei et al., 2012).
We were motivated to perform an integrative study of intraleuke-
mic genetic and DNA methylation heterogeneity in CLL because
(1) recent studies have suggested that both epigenetic marks
and genetic alterations can improve prognostic models of CLL
(Kulis et al., 2012; Rossi et al., 2013); (2) higher methylation vari-
ability has been detected across cancer subtypes compared
with healthy tissue-matched samples, including in other B cell814 Cancer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc.malignancies (Berman et al., 2012; De et al., 2013; Hansen
et al., 2011); and (3) the availability of whole-genome bisulfite
sequencing (WGBS) and reduced-representation bisulfite
sequencing (RRBS) now enables genome-wide investigation of
DNA methylation at single base pair resolution and with local
sequence context. In particular, RRBS constitutes a cost-effec-
tive approach that allows the study of large patient cohorts
(Boyle et al., 2012).
We thus performed WGBS and RRBS on a large cohort of pri-
mary patient samples that were previously characterized by
whole-exome sequencing (WES) (Landau et al., 2013), to assess
intraleukemic DNA methylation heterogeneity in CLL.
RESULTS
Increased Intrasample DNA Methylation Heterogeneity
in CLL Arises from Locally Disordered Methylation
Tomeasure intrasample CLLDNAmethylation heterogeneity, we
compared WGBS data generated from two CLL cases and two
healthy donor B cell samples (Figure 1A). We observed globally
decreased methylation in CLL compared with normal B cells,
with focally increased methylation of CpG islands (CGIs) (Fig-
ure 1A, top; Figures S1A–S1C available online), as previously
reported in CLL and other cancers (Baylin and Jones, 2011; Kulis
et al., 2012), but also a markedly increased frequency of
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Methylation Disorder and Intratumoral Heterogeneityintermediate methylation values in CLL (Figure 1A, bottom; Fig-
ures S1A–S1D), pointing to a large proportion of CpGs that are
methylated in some cells in the sample and unmethylated in
others. We reanalyzed published WGBS and Illumina 450 K
methylation array data (Kulis et al., 2012) and confirmed the
increased cell-to-cell variability in CpG methylation in CLL
compared with normal B cells (Figures S1E–S1H).
We next applied RRBS to 104 primary CLL samples that had
been previously characterized by WES (Landau et al., 2013) (Ta-
bles S1 and S2) and examined mean CpG variance. Consistent
with the WGBS data, a greater than 50% increase in intrasample
methylation heterogeneity was detected in CLL cells compared
with 26 normal B cell samples (Figure 1B). We considered two
possible sources for intrasample heterogeneity: variability be-
tween concordantly methylated fragments (i.e., whereby CpGs
in an individual fragment are consistently methylated or unme-
thylated; Figure 1C, left) and variability within DNA fragments
(i.e., discordant methylation by which CpGs in an individual frag-
ment are variably methylated; Figure 1C, right).
On the basis of established observations that short-range
methylation is highly correlated in normal physiological states
(Eckhardt et al., 2006; Jones, 2012), we initially hypothesized
that intrasample heterogeneity in CLL stems from variability be-
tween concordantly methylated fragments, reflecting a mixture
of subpopulations with distinct but uniformmethylation patterns.
To test this, we focused on CpGs covered by reads containing
four or more neighboring CpGs, as previously suggested
(Landan et al., 2012), and with sufficient read depth (greater
than 10 reads per CpG, with 6.5 million CpGs/sample covered
by 100-mer WGBS reads, and an average of 307,041 [range
278,105–335,977] CpGs/sample covered by 29-mer RRBS
reads). Contrary to the expected hypothesis, we found that
67.6 ± 3.2% (average ± SD) of the intratumoral methylation vari-
ance resulted from discordantly methylated reads across the
104 CLL samples (p = 3.24 3 1035; Figure 1D). Similarly, the
CLL WGBS confirmed a higher proportion of heterogeneously
methylated CpGs in the discordant reads compared with the
concordant reads (Figure S1E, right). These results demonstrate
that methylation heterogeneity in CLL arises primarily from vari-
ability within DNA fragments, which we have therefore termed
‘‘locally disordered methylation.’’
We performed several analyses to exclude potential alterna-
tive explanations to these findings, including the impact of
contaminating nonmalignant cells (Figure S1I), allele-specific
methylation (Figures S1J–S1L), the contribution of reads that
cover an ordered transition point from one methylation state to
another (Figure S3L), and technical biases (see Supplemental
Experimental Procedures). The sex chromosomes were
excluded from this analysis to avoid possible confounding sex
chromosome-specific effects. In addition, CLL genomes are
near diploid (Brown et al., 2012), and therefore the analysis
was not significantly affected by somatic copy number variations
(see Supplemental Experimental Procedures and Figure S1O).
To quantify the magnitude of this phenomenon across large
collections of normal and malignant human tissues, we analyzed
RRBS data not only from the 104 CLL and 26 B cell samples but
also from 45 solid and blood cancer cell lines and from 27 pri-
mary human tissue samples (Table S2). We then calculated the
proportion of discordant reads (PDR) as the number of discor-Cadant over the total number of reads for each CpG in the
consensus set (Figure 1E). As expected, we found that the
average PDR was higher in CLL compared with normal B cells
(p = 5.60 3 1014). Similarly, we found higher PDR in cancer
cell lines compared with a diverse collection of healthy human
tissue samples (p = 4.353 1012; Figure 1F). These results sup-
port the idea that locally disordered methylation is a general
property of the malignant process.
Locally Disordered Methylation Broadly Affects the CLL
Genome
To determine whether specific elements in the genome harbor
higher levels of locally disordered methylation in CLL compared
with normal B cells, we calculated the average PDR across
the 104 CLL samples and 26 healthy donor B cell samples
(Table S3).
In normal B cells, PDR levels were lowest in regions with major
roles in gene regulation (promoters, CGIs, exons, enhancers)
and higher in regions with presumably less of a regulatory role
(CGI shelves and shores, intergenic regions). In CLL, PDR was
higher across all measured regions (Figure 2A), regardless of
whether they were relatively hypermethylated (e.g., CGIs) or hy-
pomethylated (e.g., intergenic regions) compared with normal B
cells (Figure 2B). This phenomenon appeared to be neither spe-
cific to a subregion of CGIs or promoters (e.g., CGI borders; Fig-
ure 2C) nor restricted to a subtype of CGI (Figure S2A). Increased
PDR in CLL was also observed in highly repetitive DNA se-
quences (e.g., long interspersed elements [LINE] and long ter-
minal repeat retrotransposons; Figure 2A, RRBS data, and
Figure S2B, WGBS data), which largely account for the global
DNA hypomethylation observed in cancer (Ehrlich, 2009).
Alterations in the DNAmethylation regulatory machinery could
affect PDR. Unlike other hematological malignancies (Ley et al.,
2010), somatic mutations affecting direct DNAmethylation mod-
ulators in CLL are rare (Landau et al., 2013). Nonetheless, three
CLL samples with such somatic mutations (DNMT3A-Q153*,
TET1-N789I, and IDH1-S210N) showed increased PDR
compared with the 101 CLL samples wild-type for these genes
(Figure S2C).
Locally Disordered Methylation Appears to Be a Largely
Stochastic Process
Two observations in the data suggest that PDR measures a
process that stochastically increases variation in methylation, a
notion that was recently conceptualized as a feature of the can-
cer epigenome (Pujadas and Feinberg, 2012). First, the perva-
siveness of locally disordered methylation across every region
evaluated in CLL compared with B cells supports a stochastic
genome-wide process. Second, consistent with a stochastic
process, wherein the expected rate of increase in PDR would
be related to the starting level of disorder, we observed a larger
relative PDR increase in CLL in regions with lower PDR in normal
B cells. To formallymeasure the level of disorder, we undertook a
parallel analysis to calculate Shannon’s information entropy of
intrasample methylation variation (Figure S3A). We determined
this entropy to be higher in CLL than in normal B cells (as well
as higher in cancer cell lines compared with normal tissues),
consistent with an increase in stochastic ‘‘noise’’ (Figures S3B
and S3C).ncer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc. 815
Figure 2. Locally Disordered Methylation
Affects All Genomic Regions in CLL,
Including CGIs and Repeat Regions
(A and B) Comparison of mean PDR (A) and
mean CpG methylation (B) per genomic region
between CLLs and normal B cells using RRBS
data (Table S3 provides the average number of
CpGs analyzed for each genomic region). Error
bars represent upper 95% CI of the mean.
(C) Top: the distribution of PDR and methylation
across all promoters covered by RRBS for
randomly selected six CLL and six normal B cell
samples. The distribution was derived by dividing
each promoter into 100 bins and then averaging
methylation and PDR for CpGs falling into each bin
across all promoters in the sample. The PDR and
methylation values in the adjacent 2KB upstream
and downstream are also shown. Bottom: an
analogous analysis of CGIs and adjacent shore
regions.
See also Figure S2 and Table S3.
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Methylation Disorder and Intratumoral HeterogeneityTo model the relationship between methylation and PDR un-
der completely stochastic conditions, we plotted the expected
distribution of PDR for any level of methylation assuming a purely
random assignment of methylation states at each individual CpG
(Figure 3A; see Supplemental Experimental Procedures). Strik-
ingly, the distribution of measured PDR and methylation values
of 14,000 individual promoter CGIs from CLL WGBS data
closely followed the pattern of the modeled stochastic process
(Figure 3B). In outlier genes (i.e., those with less promoter PDR
than expected on the basis of the promoter methylation level;
n = 195 [1.4%]; Table S4 and Figure S3D), imprinted genes
were enriched (Morison et al., 2005) as expected, because these
are hemimethylated under normal physiological conditions (n =
10, Fisher’s exact test p = 1.94 3 106). In addition, the outlier
genes contained at least three tumor suppressor genes (WIF1,
DUSP22, and DCC) that have established roles in hematopoietic
malignancies (Chim et al., 2008; Inokuchi et al., 1996; Jantus
Lewintre et al., 2009) and also had >10% higher methylation in
the CLL169 sample compared with the normal CD19+ B cell
sample.
Similar to promoters, methylation of 1,900 LINE repeat ele-
ments also displayed a similar relationship between methylation
and PDR (Figure 3C). A comparable distribution was observed
for other genomic features (Figure S3E) andwith RRBS data (Fig-
ure S3F). This pattern was also found in promoter CpGs of tumor
suppressor genes implicated in lymphoproliferation, such as
WT1 (Menke et al., 2002) and DAPK1 (Raval et al., 2007)
(Figure S3G).816 Cancer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc.Altogether, these data support the
hypothesis that the most commonly
described cancer-related methylation
alterations (Baylin and Jones, 2011)—
increased methylation of CGIs and
decreased methylation in repeat re-
gions—are generated largely through a
seemingly stochastic process. Indeed,
across the 104 CLLs, sample average
promoter CGI PDR was highly correlatedwith an increase in sample average promoter CGI methylation
(Pearson’s correlation coefficient r = 0.90, p = 1.01 3 1038;
Figure 3D). When this analysis was repeated with genes group-
ed on the basis of their average methylation level across the
samples, this strong correlation was positive for genes with
methylation < 0.5 and negative for genes with methylation >
0.5, as expected from the previously described distribution in
Figure 3B (Figure S3H). Overall, a key implication of this analysis
is that a change in CGI methylation in CLL does not arise from
alteration in a relatively small proportion of cells with uniformly
methylated alleles but rather from a larger proportion of cells
with randomly scattered methylation. We likewise observed
sample average LINE repeat elements PDR to be correlated
with a decrease in methylation (r = 0.32, p = 6.99 3 104;
Figure 3E).
These data reveal that DNAmethylation changes in this cancer
predominately arise from a disordered change inmethylation, re-
sulting in a strong correlation between difference in PDR (DPDR)
and difference in methylation (DMeth). Because previous reports
have indicated that a large degree of methylation disorder oc-
curs during normal differentiation (Landan et al., 2012), we
sought to compare the correlation between DPDR and DMeth
among pairs of cancer and normal samples with the correlation
between pairs of healthy human tissues. Indeed, the correlation
coefficient between DPDR and DMeth was significantly higher
when CLL samples were paired to either normal B cells or to
other healthy primary tissue samples, compared with the pairing
of healthy primary tissues against either normal B cells or other
Figure 3. Locally Disordered Methylation in CLL Is Consistent with a Stochastic Process
(A) We developed a model to determine the probability of observing any PDR value in a random CpGmethylation state model, given (1) the total number of reads
that cover the locus, (2) the number of neighboring CpGs contained in individual reads, and (3) the locus methylation level. The plot demonstrates the case in
which a locus is covered at a read depth of 30 and each read contains four neighboring CpGs. The expected PDR value is shown by the dashed line, and the
shaded region represents methylation-PDR tuples with a probability greater than 0.01 under the random model.
(B) The CLL methylation data are consistent with the stochastic pattern shown in (A). Average promoter CGI methylation and PDR were calculated for 13,943
CGIs covered by WGBS (more than ten CpGs per island) in both the CLL and the normal B cell samples. Outliers represent 1.4% of events (see Figure S3D and
Table S4).
(C) Average LINE element methylation and PDR were calculated for 1,894 elements covered by WGBS (>20 CpGs per element) in the same samples as in (B).
(D) The correlation in CLL between sample average of CGI methylation and PDR is shown (8,740.2 ± 3,102.8 promoter CGIs per sample were evaluated; see also
Figure S3E).
(E) Similarly, the correlation in CLL between sample average LINE element methylation and PDR are also shown. The RRBS-based results of CLL169 are
highlighted with a purple square.
(F) To study the correlation betweenDPDR and DMeth, we paired representative CLL and normal B cell samples. For each promoter (>20 CpGs per promoter, n =
2,119), DMeth and DPDR were plotted (red). An identical procedure was performed with a pairing of the same normal B cell sample to an adult lung sample
(Lung_normal_BioSam_235, blue). These data enable the comparison between the Pearson’s coefficient for the correlation betweenDPDR andDMeth in cancer-
related changes versus normal physiological state changes.
(G) To confirm this finding across the entire data set, random pairings were performed in each category listed on the x axis, avoiding repeated use of any individual
sample within a category. This procedure was repeated 100 times, and the means of the correlation coefficients for each iteration are plotted and compared.
See also Figure S3 and Table S4.
Cancer Cell
Methylation Disorder and Intratumoral Heterogeneityhealthy tissue samples (Figures 3F and 3G). Thus, methylation
changes associated with the malignant process differ substan-
tially from those that occur during changes in physiological
cellular states and show a significantly higher degree of methyl-
ation disorder.CaIncreased Susceptibility to Locally Disordered
Methylation in Gene-Poor Regions and Silent Genes
Some regions of the genome may be more prone to stochastic
variation in methylation (Pujadas and Feinberg, 2012). We found
3-fold higher promoter PDR in regions with the lowest genencer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc. 817
Figure 4. Locally Disordered Methylation Affects Preferentially Gene-Poor Regions and Can Be Traced Back to Nonexpressed Genes in
Normal B Cells
(A) Promoter PDR (orange, error bars represent 95% CIs of means) in relation to gene density (genes/MB, left) and CTCF binding site density (right) regions. As
reference, the CpG content is also provided (black).
(B) PDR and methylation in hypomethylated blocks (Hansen et al., 2011) is plotted for CLL and normal B cells (shown are blocks with >1,000 CpGs in WGBS; see
also Figure S4A for comparison with a matched set of control genomic blocks).
(C) Replication time and PDR are correlated; PDR was averaged for each promoter covered in >70% of 104 CLLs, and these values were grouped in replication
time bins.
(D) To assess the relationship between somatic mutations and PDR, sSNVs were identified with whole-genome sequencing of matched tumor and germline DNA
(CLL169). Average PDR (left) and methylation (right) were measured in 1,000 bp increments from each somatic mutation. Values of CpGs in each 1,000 bp bin
were averaged over 4,973 sSNVs and plotted as a function of the distance from the somatic mutation. Orange lines denote the locally weighted scatterplot
smoothing. See Figures S4B and S4C for an analysis performed separately for clonal and subclonal mutations.
(E) Left: promoter CGI PDR is correlated between CLL and normal B cell samples (Pearson, evaluatedwith 5,811 consistently covered CGIs). Right: promoter CGI
PDR in B cells and CLLs is shown for genes expressed and not expressed in normal B cells (FPKM< 1, n = 1,002 fromRNA-seq data of seven healthy donor B cell
samples).
See also Figure S4.
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Methylation Disorder and Intratumoral Heterogeneitydensity compared with those with highest gene density (with
similar correlations to CTCF density; Figure 4A). In addition, pre-
viously described hypomethylated blocks are regions notable for
their association with the nuclear lamina and furthermore are en-
riched with genes that have high expression variability in cancer
and impact critical cellular processes such as mitosis and cell
cycle control (Hansen et al., 2011; Timp and Feinberg, 2013).
In these regions as well, we observed a significant PDR increase
in CLL (Figures 4B and S4A). Finally, in concert with these find-
ings, we observed higher promoter PDR in genes with later repli-818 Cancer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc.cation time across the 104 CLL samples (r = 0.35, p = 1.3 3
10153; Figure 4C), in agreement with other recent reports (Ber-
man et al., 2012; Shipony et al., 2014). Notably, late replication
time is closely associated with increased somatic mutation
rate (Lawrence et al., 2013). Thus, similar genomic regions may
share lower genetic and epigenetic fidelity, as we observed in
a joint analysis of somatic single-nucleotide variants (sSNVs)
and locally disordered methylation (Figures 4D, S4B, and S4C).
As many features of chromatin and spatial organization may
be shared between the CLL and normal B cell genomes, we
Figure 5. Locally Disordered Methylation Is
Associated with Transcriptional Variation
(A) Mean promoter PDR and gene expression are
correlated (evaluated with 8,570 genes that had
promoter RRBS coverage in >70% of 33 samples
with matched RRBS and RNA-seq, the number of
genes evaluated within each expression range
provided in Figure S5A, and mean expression and
methylation correlation is provided in Figure S5B.
(B) PDR and expression variability as measured
with CV of 5,874 transcribed genes (FPKM > 1).
Black circles (brackets) denote mean CV (95% CI)
for genes within PDR bins (number of genes per
bin in blue). Red line is the cubic smoothing spline
of CV and PDR values (unbinned). Note that the
analysis was limited to transcribed genes to avoid
an artificial enhancement of the CV that occurs
with very low mean expression values. Because
>97.5% of transcribed genes had PDR < 0.3, we
limited the x axis to PDR < 0.3.
(C) Left: OR (bars denote 95% CI) for gene
expression (FPKM> 1) with amethylated promoter
(average methylation > 0.8) versus an un-
methylated promoter (average methylation < 0.2)
is calculated for genes with high (orange, 27.5 ±
2.6% of genes) or low promoter PDR (black).
Right: linear models that combine information
from all 33 CLLs as continuous variables to predict
expression.
(D) PDR and intrasample gene expression het-
erogeneity (assessed by Shannon’s information
entropy) across the range of population average
expression (fragments per million [FPM]), by sin-
gle-cell RNA-seq of 84 cells from CLL005 (see
Figure S5D for analysis of three additional CLL
samples). Local regression lines for genes with low
PDR (0–0.05, blue), intermediate PDR (0.05–0.2,
purple), and high PDR (0.2–1.0, red) are shown.
(E) Results of generalized additive regression tests
that model single-cell gene expression Shannon’s
information entropy on the basis of PDR, popula-
tion average expression, and transcript length
across the four CLL samples.
(F) Single-cell gene expression patterns for genes
within a narrow population average expression
range of 1.0 to 1.2 (black rectangle in D). Consistent with the higher gene expression Shannon’s information entropy observed in genes with higher PDR (top),
genes with low PDR (bottom left) tend to be expressed at highmagnitude (larger dot size) in fewer cells, whereas genes with high PDR (bottom right) are frequently
expressed at low expression magnitudes across many cells.
See also Figure S5 and Tables S5 and S6.
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Methylation Disorder and Intratumoral Heterogeneityhypothesized that some degree of locally disorderedmethylation
might exist in normal B cells in regions with high PDR in CLL. In
fact, average PDR of individual CGI in CLL and B cell samples
was highly correlated (r = 0.83, p < 2 3 1016; Figure 4E, left).
Thus, the promoters with highest PDR in CLL already have
increased PDR in normal B cells. Consistent with the notion
that nonexpressed genes are the most vulnerable to aberrant
methylation (Meissner et al., 2008), promoter CGIs with a high
PDR in both CLL and normal B cells were often found in genes
not expressed in normal B cells (Figure 4E, right).
Locally Disordered Methylation and Gene Expression
To examine the relationship between locally disordered DNA
methylation and gene expression in more detail, we analyzed
matched RRBS and RNA sequencing (RNA-seq) profiles of 33CaCLL samples (Table S5; PDR and methylation calculated on the
basis of an average ± SD of 12.1 ± 4.8 CpGs per promoter). As
in normal B cells, in the 33 CLL samples, PDR was inversely
correlated with gene expression (r = 0.51, p < 2 3 1016; Fig-
ures 5A, S5A, and S5B). Notably, whereas promoter PDR was
negatively correlatedwithmean transcript levels, it was positively
correlated with intersample variation in transcript levels (Fig-
ure 5B). Although it may be difficult to definitively deconvolute
the positive correlation between PDR and expression variation
from the strong negative correlation of mean expression and
expression variation, both low gene expression and high pro-
moter PDR levelswere predictive of higher coefficient of variation
(CV) of gene expression in a linear model (p < 23 1016 for both).
To further examine the impact of locally disordered methyl-
ation in CLL on expression levels, we calculated the odds rationcer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc. 819
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Methylation Disorder and Intratumoral Heterogeneity(OR) of gene expression (defined as fragments per kilobase of
exon per million fragments mapped (FPKM) > 1) with a methyl-
ated promoter (defined as methylation > 0.8, unmethylated
defined as < 0.2). Promoters with low PDR (i.e., lower than the
mean PDR [mean ± SD promoter PDR was 0.10 ± 0.01]) tended
to preserve the expected relationship between promoter methyl-
ation and expression and rarely generated transcripts in the
presence of a methylated promoter. Across 33 CLL samples,
the average OR was 0.043 (range 0.036–0.050). In contrast,
genes with high PDR promoters (greater than the mean PDR)
had a greater likelihood of undergoing transcription (OR 0.396,
range 0.259–0.698, Wilcoxon p = 6.5 3 1011; Figure 5C),
despite comparable promoter methylation levels. As a repre-
sentative example, we show ZNF718 in two samples with com-
parable levels of promoter methylation (0.82 in CLL062, 0.87 in
CLL074) but low promoter PDR (0.04) in the former and high pro-
moter PDR (0.24) in the latter. Consistent with the OR analysis
above, we observed undetectable expression in CLL062
(FPKM of 0.03) and measurable RNA expression in CLL074
(FPKM of 5.6) (Figure S5C).
These observations demonstrate how locally disordered
methylation and epigenetic heterogeneity may contribute to
increased transcriptional variation. To assess the relationship
between PDR and gene expression as continuous variables,
we used linear models to predict expression on the basis of
methylation information. Across the 33 samples, a univariate
model that predicts expression on the basis of average promoter
methylation yielded an adjusted R2 value of 0.092, whereas one
using promoter PDR yielded an average adjusted R2 value of
0.202. Inclusion of additional features such as CpG and repeat
content only modestly improved the predictive power of the
model (average adjusted R2 = 0.214; Table S6). Indeed, the
addition of PDR information to a model that uses promoter
methylation to predict gene expression as a continuous variable
(evaluated for 320,574 matched values of expression and
methylation from 33 CLLs) resulted in a significant improvement,
with more than doubling of the model’s explanatory power
(increase in adjusted R2 value from 0.0915 to 0.1992, likelihood
ratio test p < 13 1016). This held true when the model included
only genes with lowly methylated or only genes with highly meth-
ylated promoters (p < 1 3 1016). Even after adding additional
variables such as repeat element content, the presence of a
CGI in the promoter, and CpG content, PDR remained the stron-
gest predictor of expression (Figure 5C, right).
Single-Cell Gene Expression Patterns of Genes with
Disordered Promoter Methylation
We next isolated 96 individual cells from four CD19+CD5+ puri-
fied CLL samples and generated single-cell full-length transcrip-
tomes using SMART-seq (Clontech; 75–84 cells analyzed per
sample after excluding cells with < 1 3 104 aligned reads; Table
S2). Promoter PDR was associated with significantly higher in-
tratumoral expression information entropy in all four samples
(p < 1.4 3 108; Figures 5D, 5E, and S5D), in a model that
included transcript length as well as population average gene
expression (see Supplemental Experimental Procedures), which
is the variable associated most closely with technical noise in
single-cell transcriptome analyses (Shalek et al., 2014). These
results remained significant even after the addition of promoter820 Cancer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc.methylation to the model (Figure S5E). Because expression
information entropy may be affected by variation in sampling
of lowly expressed transcripts, we compared the single-cell
expression patterns of genes with low or high promoter methyl-
ation disorder but with similar population average expression
levels (Figure 5F). We observed that high promoter PDR genes
tend to be expressed in larger numbers of cells at lower expres-
sion magnitude, whereas low promoter PDR genes tend to be
expressed in smaller numbers of cells at higher expression
magnitude. Thus, promoter methylation disorder correlates
with an intermediate transcriptional state that interferes with
both complete silencing and high-level expression.
Locally DisorderedMethylation Affects StemCell Genes
and May Facilitate Leukemic Evolution
Increased epigenetic ‘‘noise’’ would be expected to generate a
more plastic evolutionary landscape that facilitates the emer-
gence of fitness-enhancing genetic and epigenetic alterations.
To explore the potential relationship between locally disordered
methylation and selection, we identified differentially methylated
regions (DMRs) in promoters and CGIs, because the presence of
recurrent epigenetic alterations might signal the presence of
evolutionary convergence. In fact, these DMRs were associated
with significantly higher PDR, suggestive of positive selection
operating against a backdrop of stochastic epigenetic heteroge-
neity (Figure S6A).
Furthermore, a gene set enrichment analysis of genes with
consistently high promoter PDR across CLL samples compared
with genes with consistently low promoter PDR revealed enrich-
ment in TP53 targets (Perez et al., 2007), in genes differentially
methylated across various malignancies (Acevedo et al., 2008;
Sato et al., 2003), and in gene sets associated with stem cell
biology (Lim et al., 2010; Wong et al., 2008) (BH-FDR Q < 0.1;
Figures 6A and S6B; Table S7). Finally, regions that are specif-
ically hypomethylated in human embryonic stem cells com-
pared with a diverse collection of differentiated cells (Ziller
et al., 2013) also showed decreased methylation and increased
PDR in CLL compared with normal B cells, suggestive of a drift
toward a more stem-cell-like state (Figure 6B). Collectively,
these findings suggest that locally disordered methylation cre-
ates a rich substrate for CLL evolution by stochastic variation
amenable to positive selection and by increasing the number
of cells that carry the potential to propagate new genotypes
to progeny populations. Indeed, CLLs with a higher number
of subclonal mutations also exhibit higher PDR (p = 0.002;
Figure 6C).
To directly observe the relationship between genetic and
epigenetic evolution, we studied RRBS data from 14 longitudi-
nally sampled CLL patients with characterized patterns of ge-
netic evolution (median time between samples 3.45 years; 9
CLLs with and 5 without evidence of genetic evolution; Table
S8). CLLs that underwent genetic clonal evolution also had
increased average promoter PDR over time (paired t test, p =
0.037; Figure 6D), which may indicate a higher PDR in the
subclone that expanded over time. In addition, genes with pro-
moters that were demethylated over time, were significantly en-
riched for the same aforementioned stem cell-related gene sets
(Boquest et al., 2005; Jaatinen et al., 2006; Lim et al., 2010;Wong
et al., 2008) (Figure 6E; Table S9). Importantly, the correlation
Figure 6. Locally Disordered Methylation
May Interact with Evolution through Drift to-
ward a Stem-like State
(A) Gene set enrichment analysis comparing 1,668
genes with consistently high promoter PDR (>0.1
in >75% of samples) with 5,392 genes with
consistently low promoter PDR (<0.1 in >75% of
samples, selected ten gene sets displayed; see
Table S7 for the top 30 enrichments). Enrichment
in genes with consistently high PDR was calcu-
lated for hypergeometric distribution followed by
BH-FDR (‘‘Q(high)’’). In addition, enrichment in
high-PDR genes versus low-PDR genes was
calculated using Fisher’s exact test followed by
BH-FDR (‘‘Q(high versus low)’’).
(B) PDR and methylation in regions hypomethy-
lated in embryonic stem cells (Ziller et al., 2013), in
CLL compared with normal B cells (WGBS data).
Regions include 91 enhancers (e.g., POU5F1,
NANOG), 41 enhancer CGIs (e.g., TET2, EP400),
six CGIs (e.g., DAPK1), six promoters, and 84
other putative regulatory elements (e.g.,DEC1 and
POT1) (Ziller et al., 2013). The inset shows indi-
vidual changes of selected regions.
(C) PDR in CLLs with high versus low numbers of
subclonal (median 7.5 sSNVs) and clonal muta-
tions (median 10 sSNVs).
(D) Fourteen CLLs were sampled longitudinally at
two time points (T1 and T2; median interval time
3.5 years), and change in PDR over time was
compared between CLLs that underwent genetic
clonal evolution (n = 9) and those without genetic
evolution (n = 5) (paired t test).
(E) Gene set enrichment of the 899 genes from the
14 cases with significant promoter methylation
change between time points T1 and T2 (absolute
change > 10%, FDR BH Q < 0.1) in genes with
promoter demethylation over time (456 genes),
and in genes with promoter methylation over time
(443 genes; see Table S9 for top 30 enrichments).
See also Figure S6 and Tables S7–S9.
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Methylation Disorder and Intratumoral Heterogeneitycoefficient between DPDR and DMeth was markedly lower for
gene promoters that were significantly demethylated or hyper-
methylated over time (r = 0.0937 and r = 0.0987, respectively),
compared with the correlation coefficient for gene promoters
without significant changes in methylation (r = 0.4163; 144,161
promoters across 14CLLs). These results suggest that gene pro-
moters with significant changes in methylation over time were
enriched for genes that underwent ordered methylation change,
as expected from positive selection.Cancer Cell 26, 813–825,Locally Disordered Methylation
Affects Clinical Outcome
The presented data support a model in
which locally disordered DNA methyl-
ation facilitates tumor evolution through
increased genetic and epigenetic plas-
ticity. Thus, we hypothesized that in-
creased PDR would be associated with
a shorter remission time after treatment,
which we previously linked with clonal
evolution (Landau et al., 2013).We therefore examined failure-free survival after treatment
(FFS; failure defined as retreatment or death) in 49 patients
included in the cohort who were treated after tumor sampling
for RRBS. A higher mean sample promoter PDR (greater than
the mean for the cohort) was significantly associated with
shorter FFS (median FFS of 16.5 versus 44 months, hazard ratio
2.5, 95% confidence interval [CI] 1.1 to 5.7, p = 0.028, Figure 7A;
52% and 65% of patients, respectively, were treated with flu-
darabine-based immunochemotherapy, p = 0.39). A regressionDecember 8, 2014 ª2014 Elsevier Inc. 821
Figure 7. Locally Disordered Methylation Is
Associated with Adverse Clinical Outcome
(A) Kaplan-Meier plot showing FFS time (failure
defined as retreatment or death from the time of
first therapy after RRBS analysis) in CLLs with
higher versus lower than average promoter PDR.
Note that the analysis could be performed only for
the 49 patients who received therapy after RRBS
sampling.
(B) Multivariate analysis for this association with
the addition of well-established poor outcome
predictors in CLL (IGHV unmutated status, del
[17p] and del[11q]), as well as with the addition of
the presence of a subclonal driver (including so-
matic copy number changes, sSNVs, and indels),
as previously described (Landau et al., 2013), to
the model.
See also Table S10.
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tated status, del[17p] and del[11q]) showed an adjusted hazard
ratio of 2.81 (95% CI 1.05–7.53, p = 0.039, Figure 7B) for high
promoter PDR. Similar results were obtained after the inclusion
of additional variables in the model, including mutation burden
and average promoter methylation (Table S10). Samples with
higher promoter PDR were also more likely to have a subclonal
driver mutation as previously defined (Landau et al., 2013) (p =
0.01). When the presence of a subclonal driver was added to the
regression model, the increased risk associated with the
elevated PDR was no longer preserved (Figure 7B). These re-
sults support the notion that epigenetic ‘‘noise’’ may function
primarily as a facilitating feature, allowing the emergence of
subclonal drivers, which then contribute to the adverse clinical
outcome.
DISCUSSION
Cancer epigenomes have been long appreciated to differ from
their normal tissue counterparts (Baylin and Jones, 2011). Global
hypomethylation of cancer DNA was described as early as the
1980s, with frequent focal hypermethylation of key regulatory re-
gions (Jones and Baylin, 2007). Recent genome-wide mapping
have further highlighted alterations likely to contribute to the
malignant process such as the epigenetic silencing of tumor
suppressor genes and the activation of genes in stem-like
cellular programs (Akiyama et al., 2003; Jones and Baylin, 2007;
Widschwendter et al., 2007).
We now report the analysis of DNA methylation in primary leu-
kemia cells that reveals another fundamental difference between
cancer and normal methylomes: locally disordered methylation
arising from a stochastic process, which leads to a high degree
of intrasample methylation heterogeneity. These findings further
advance key concepts described in several prior reports (Ber-
man et al., 2012; Hansen et al., 2011; Landan et al., 2012; Mae-
gawa et al., 2014; Pujadas and Feinberg, 2012; Siegmund et al.,
2009). Thus, as previously suggested (Timp and Feinberg, 2013),
cancer epigenomes may accommodate a higher amplitude of
epigenetic ‘‘noise’’ and thereby allow cancer cells a greater de-
gree of population diversity. Analogous to the role of genetic
instability, which fuels cancer plasticity by facilitating the acqui-
sition of somatic alterations at random locations across the822 Cancer Cell 26, 813–825, December 8, 2014 ª2014 Elsevier Inc.genome (Hanahan and Weinberg, 2011), we propose that sto-
chastic methylation changes enhance epigenetic plasticity and
likewise enable tumor cells to better explore the evolutionary
space in search of superior fitness trajectories.
These data alter the way we understand differential methyl-
ation in cancer. First, the insight that stochastic variation under-
lies the bulk of CLL methylome heterogeneity signifies that
changes in methylation measured between cancer and normal
cells do not likely reflect a uniform change in methylation state
of a given region but rather a disordered methylation change
involving differing, isolated CpGs, affecting many cells in the
cancer population. Second, these data suggest improved
methods from which we can identify fitness-enhancing DMRs.
We can draw from the lessons of the computational analyses
of large cancer genome sequencing data sets, in which a better
understanding of the variation in the distribution of gene muta-
tions has led to an improved ability to distinguish ‘‘driver’’ from
‘‘passenger’’ mutations (Lawrence et al., 2013). In an analogous
fashion, we anticipate that appreciation of the extent of locally
disordered methylation provides an appropriate background
model against which a departure from the stochastic regime
would indicate positively selected DMRs. We note that only a
small proportion of methylation events fall outside the predic-
tions of the stochastic model, suggesting very few of the
changes in methylation undergo positive selection.
These data moreover demonstrate that locally disordered
methylation is associated with a more ‘‘noisy’’ transcriptional
landscape, with a decoupling of the relationship between pro-
moter methylation and gene expression. Our analysis suggests
that some of the epigenetic variability is likely associated with
stemlike cell programs, which have been implicated in cancer
(Kim et al., 2010; Ohnishi et al., 2014). Indeed, we detected a
concurrent decrease in methylation and an increase in PDR,
affecting regions that were identified to be hypomethylated in
human embryonic stem cells, consistent with the notion that sto-
chastic noise may lead to a drift toward a hybrid stem-somatic
cell state (Timp and Feinberg, 2013). Furthermore, in CLLs that
were directly observed to undergo genetic diversification and
evolution over time, stem cell-related genes with higher pro-
moter PDR also underwent demethylation over time. Thus,
increased stochastic variation may blur the lines between popu-
lations with different proliferative potentials and thus increase
Figure 8. Proposed Interaction between
Methylation Disorder and Clonal Evolution
A novel somatic mutation (depicted with lightning
bolts) would have to coincide with an epigenetic
state that will be permissive to the propagation of
the new genotype to a progeny population. In
a cellular population with limited stochastic
methylation changes (top), the proportion of cells
that are therefore able to actively participate in the
evolutionary process is small. However, in a more
malleable epigenetic landscape, such as ex-
pected to result from a high level of locally disor-
dered methylation, a greater proportion of cells
can give birth to new subclones, increasing the
diversity and the adaptive capacity of the cancer
population, resulting in adverse clinical outcome
with therapy.
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Methylation Disorder and Intratumoral Heterogeneitythe diversity of adaptive mechanisms available to the cell, a
hedging strategy for enhanced survival (Bala´zsi et al., 2011).
A further extension of thismodel proposes that locally disorder
methylation enhances the evolutionary capacity of CLL by opti-
mizing the process of genetic diversification. This framework
would necessitate coincidence of a novel somatic mutation
with an epigenetic state permissive to the propagation of the
new genotype to a progeny population. In cellular populations
with a preserved epigenetic landscape (Figure 8, top), the pro-
portion of cells capable of actively participating in the evolu-
tionary process is predicted to be small. On the other hand, in
a more malleable epigenetic landscape (Figure 8, bottom) as is
expected with a high level of locally disordered methylation, a
greater proportion of cells can give birth to new subclones.
This process would accelerate genetic evolution, provide a
greater adaptive capacity for the cancer population, and result
in adverse clinical outcome with therapy, as we saw in our CLL
cohort.
What is the basis of increased locally disordered methylation
in CLL? Although the exact mechanism remains to be fully eluci-
dated, we speculate that the considerably higher replication rate
in CLL compared with their normal differentiated counterparts
could contribute to accumulation of stochastic lapses in methyl-
ation inheritance in cancer cells, given the estimated error rate
of 0.08% to 4% for a given CpG per cell division (Bird, 2002;
Ushijima et al., 2003). This maybe further compounded by the
occurrence of genetic lesions in essential components of the
methylation machinery. In addition, the finding that locally disor-
der methylation in CLL tended to be highest in gene-poor and
late-replicating regions suggests that some genomic regions
exhibit even higher error rates, consistent with the previously
observed high cancer intersamplemethylation variability in these
regions (Hansen et al., 2011).
Our data suggest that evolution and diversity of DNA methyl-
ation in CLL result from stochastic events. This insight should
improve our model for background methylation changes in can-Cancer Cell 26, 813–825,cer and allow more rigorous identification
of positively selectedmethylated regions.
Locally disordered DNA methylation is
likely to have a similar role to genetic
instability, providing a mechanism forcancer cells to find superior evolutionary trajectories during
tumorigenesis and in response to therapy.
EXPERIMENTAL PROCEDURES
Sample Acquisition
Peripheral blood samples were obtained from patients with CLL and healthy
adult volunteers. Informed consent on Dana-Farber Cancer Institute institu-
tional review board-approved protocols for genomic sequencing of patients’
samples was obtained prior to the initiation of sequencing studies. Genomic
DNA was extracted from CLL cells or normal B cell populations.
WGBS
WGBS was performed as described in Supplemental Experimental Pro-
cedures. Subsequently, CpG methylation calls were made using custom soft-
ware, excluding duplicate and low-quality reads. Previously published WGBS
data for two CLL samples and three normal B cell samples (Kulis et al., 2012)
were downloaded with permission and processed in identical fashion to the in-
house-produced WGBS libraries.
RRBS
RRBS was performed as described in Supplemental Experimental Proce-
dures. RRBS of primary diverse human tissue samples were previously re-
ported (http://www.roadmapepigenomics.org). Reads were aligned, and
methylation was determined using identical protocols to the rest of the
samples.
RNA-Seq
RNA-seq of CLL and normal B cell samples was performed as previously
described (Landau et al., 2013). For single-cell RNA-seq, the C1 Single-Cell
Auto Prep System (Fluidigm) was used to perform SMARTer (Clontech)
whole-transcriptome amplification (WTA), on up to 96 individual cells per sam-
ple from four primary CLL patient samples.WTA products were then converted
to Illumina sequencing libraries using Nextera XT (Illumina) (Ramsko¨ld et al.,
2012).
Statistical Analysis
Statistical analysis was performed with MATLAB (The MathWorks), R version
2.15.2 (R Foundation for Statistical Computing), and SAS version 9.2 (SAS
Institute). A complete description of the materials and methods is provided
in Supplemental Experimental Procedures. The CLL and normal B cellDecember 8, 2014 ª2014 Elsevier Inc. 823
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Methylation Disorder and Intratumoral Heterogeneitysequencing data were deposited in the database of Genotypes and Pheno-
types (dbGaP) (phs000435.v2.p1) and the processed data deposited in
Gene Expression Omnibus (GEO) (GSE58889).
ACCESSION NUMBERS
The GEO accession number for the data reported in this paper is GSE58889.
The dbGaP accession number for the sequencing data reported in this paper is
phs000435.v2.p1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and ten tables and can be found with this article online at http://
dx.doi.org/10.1016/j.ccell.2014.10.012.
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